BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note released on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Price Performance

Shares of BLRX opened at $0.11 on Monday. The stock has a 50 day simple moving average of $0.22 and a 200 day simple moving average of $0.47. BioLineRx has a 52-week low of $0.08 and a 52-week high of $1.44. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The firm has a market capitalization of $8.39 million, a PE ratio of -0.48 and a beta of 1.46.

BioLineRx shares are going to reverse split before the market opens on Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 29th.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. Sell-side analysts predict that BioLineRx will post -0.15 EPS for the current fiscal year.

Institutional Trading of BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. PVG Asset Management Corp purchased a new stake in BioLineRx Ltd. (NASDAQ:BLRX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned about 0.15% of BioLineRx at the end of the most recent quarter. 1.56% of the stock is currently owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.